Drugs / Vi Polysaccharide Vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy4 trials | ||||||
| Phase 1 | NCT03109600 Comparator | Apr → Sep 2017 | — | PT Bio Farma | Completed | No outcome recorded |
| Phase 2 | NCT03460405 Comparator | Jul 2018 → Dec 2019 | — | PT Bio Farma | Completed | No outcome recorded |
| Phase 2 | NCT01193907 Comparator | Oct → Nov 2010 | typhoid fever | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT04051268 Comparator | Mar 2020 → Nov 2021 | — | PT Bio Farma | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vi Polysaccharide Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03460405 ↗ |
| Known as | Vi-PS | “Investigational vaccine used was Vi-DT and control was Vi-PS.” PMID 38297337 ↗ Feb 2024 |
| Modality | Vaccine | “Vi polysaccharide vaccine” NCT03109600 ↗ |